Literature DB >> 20981217

Serum uric Acid as a predictor for the development of nonalcoholic Fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study.

Jae Woong Lee1, Yong Kyun Cho, Mc Ryan, Hyang Kim, Seung Won Lee, Eugene Chang, Kwan Joong Joo, Jung Tae Kim, Bum Soo Kim, Ki Chul Sung.   

Abstract

BACKGROUND/AIMS: This study evaluated the relationship between hyperuricemia and nonalcoholic fatty liver disease (NAFLD) by comparing the incidence rates of NAFLD in relation to serum uric acid levels in apparently healthy subjects during a 5-year period.
METHODS: Among 15,638 healthy Korean subjects who participated in a health-screening program in 2003 and 2008, respectively, 4954 subjects without other risk factors were enrolled in this study. We compared the incidence rates of NAFLD in 2008 with respect to baseline uric acid levels.
RESULTS: In 2003, serum uric acid levels were categorized into the following quartiles: 0.6-3.9, 3.9-4.8, 4.8-5.9, and 5.9-12.6 mg/dL. The incidence of NAFLD in 2008 increased with the level of baseline uric acid (5.6%, 9.8%, 16.2%, and 20.9%, respectively; p<0.05). Multiple logistic regression analysis demonstrated that hyperuricemia was associated with the development of NAFLD. When compared to the subjects in quartile 1, the odds ratio (OR) for the incidence of NAFLD for quartiles 2, 3, and 4 were 1.53 (95% confidence interval [CI], 1.09-2.16; p=0.014], 1.69 (95% CI, 1.17-2.44; p=0.005), and 1.84 (95% CI, 1.25-2.71; p=0.002), respectively.
CONCLUSIONS: High serum uric acid levels appear to be associated with an increased risk of the development of NAFLD.

Entities:  

Keywords:  Metabolic syndrome; Non-alcoholic fatty liver disease; Uric acid

Year:  2010        PMID: 20981217      PMCID: PMC2956352          DOI: 10.5009/gnl.2010.4.3.378

Source DB:  PubMed          Journal:  Gut Liver        ISSN: 1976-2283            Impact factor:   4.519


  27 in total

1.  Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice.

Authors:  Inmaculada García-Ruiz; Cristina Rodríguez-Juan; Teresa Díaz-Sanjuan; Pilar del Hoyo; Francisco Colina; Teresa Muñoz-Yagüe; José A Solís-Herruzo
Journal:  Hepatology       Date:  2006-09       Impact factor: 17.425

2.  Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome.

Authors:  Tae Woo Yoo; Ki Chul Sung; Hun Sub Shin; Byung Jin Kim; Bum Soo Kim; Jin Ho Kang; Man Ho Lee; Jung Ro Park; Hyang Kim; Eun Jung Rhee; Won Young Lee; Sun Woo Kim; Seung Ho Ryu; Dong Geuk Keum
Journal:  Circ J       Date:  2005-08       Impact factor: 2.993

Review 3.  'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis.

Authors:  Amedeo Lonardo; Cesare Carani; Nicola Carulli; Paola Loria
Journal:  J Hepatol       Date:  2006-04-05       Impact factor: 25.083

4.  Changes in insulin and lipid metabolism in males with asymptomatic hyperuricaemia.

Authors:  I Zavaroni; S Mazza; M Fantuzzi; E Dall'Aglio; E Bonora; R Delsignore; M Passeri; G M Reaven
Journal:  J Intern Med       Date:  1993-07       Impact factor: 8.989

5.  Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein.

Authors:  P M Abuja
Journal:  FEBS Lett       Date:  1999-03-12       Impact factor: 4.124

6.  Serum uric acid and hypertension: the Olivetti heart study.

Authors:  F Jossa; E Farinaro; S Panico; V Krogh; E Celentano; R Galasso; M Mancini; M Trevisan
Journal:  J Hum Hypertens       Date:  1994-09       Impact factor: 3.012

Review 7.  The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease.

Authors:  Arthur J McCullough
Journal:  Clin Liver Dis       Date:  2004-08       Impact factor: 6.126

8.  Hyperuricaemia: relationships to body fat distribution and other components of the insulin resistance syndrome in 38-year-old healthy men and women.

Authors:  M Cigolini; G Targher; M Tonoli; F Manara; M Muggeo; G De Sandre
Journal:  Int J Obes Relat Metab Disord       Date:  1995-02

9.  The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects.

Authors:  Ki Chul Sung; Marno C Ryan; Andrew M Wilson
Journal:  Atherosclerosis       Date:  2008-07-31       Impact factor: 5.162

10.  Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle.

Authors:  Melvin R Hayden; Suresh C Tyagi
Journal:  Nutr Metab (Lond)       Date:  2004-10-19       Impact factor: 4.169

View more
  34 in total

Review 1.  Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.

Authors:  Thomas Jensen; Manal F Abdelmalek; Shelby Sullivan; Kristen J Nadeau; Melanie Green; Carlos Roncal; Takahiko Nakagawa; Masanari Kuwabara; Yuka Sato; Duk-Hee Kang; Dean R Tolan; Laura G Sanchez-Lozada; Hugo R Rosen; Miguel A Lanaspa; Anna Mae Diehl; Richard J Johnson
Journal:  J Hepatol       Date:  2018-02-02       Impact factor: 25.083

2.  Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats.

Authors:  Laura G Sanchez-Lozada; Ana Andres-Hernando; Fernando E Garcia-Arroyo; Christina Cicerchi; Nanxing Li; Masanari Kuwabara; Carlos A Roncal-Jimenez; Richard J Johnson; Miguel A Lanaspa
Journal:  J Biol Chem       Date:  2019-01-16       Impact factor: 5.157

3.  Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD.

Authors:  Miriam B Vos; Ryan Colvin; Patricia Belt; Jean P Molleston; Karen F Murray; Philip Rosenthal; Jeffrey B Schwimmer; James Tonascia; Aynur Unalp; Joel E Lavine
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-01       Impact factor: 2.839

4.  Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey.

Authors:  Jeffrey C Sirota; Kim McFann; Giovanni Targher; Richard J Johnson; Michel Chonchol; Diana I Jalal
Journal:  Metabolism       Date:  2012-10-02       Impact factor: 8.694

5.  Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver.

Authors:  Miguel A Lanaspa; Laura G Sanchez-Lozada; Yea-Jin Choi; Christina Cicerchi; Mehmet Kanbay; Carlos A Roncal-Jimenez; Takuji Ishimoto; Nanxing Li; George Marek; Murat Duranay; George Schreiner; Bernardo Rodriguez-Iturbe; Takahiko Nakagawa; Duk-Hee Kang; Yuri Y Sautin; Richard J Johnson
Journal:  J Biol Chem       Date:  2012-10-03       Impact factor: 5.157

Review 6.  Obesity-related cardiorenal disease: the benefits of bariatric surgery.

Authors:  Wiebke Fenske; Thanos Athanasiou; Leanne Harling; Christiane Drechsler; Ara Darzi; Hutan Ashrafian
Journal:  Nat Rev Nephrol       Date:  2013-08-06       Impact factor: 28.314

Review 7.  Uric acid in metabolic syndrome: From an innocent bystander to a central player.

Authors:  Mehmet Kanbay; Thomas Jensen; Yalcin Solak; Myphuong Le; Carlos Roncal-Jimenez; Chris Rivard; Miguel A Lanaspa; Takahiko Nakagawa; Richard J Johnson
Journal:  Eur J Intern Med       Date:  2015-12-15       Impact factor: 4.487

Review 8.  Hyperuricemia and nonalcoholic fatty liver disease: from bedside to bench and back.

Authors:  Chengfu Xu
Journal:  Hepatol Int       Date:  2015-12-15       Impact factor: 6.047

9.  Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study.

Authors:  Yu-Ling Chen; Hao Li; Shu Li; Zhou Xu; Shen Tian; Juan Wu; Xin-Yu Liang; Xin Li; Zi-Li Liu; Jun Xiao; Jia-Ying Wei; Chen-Yu Ma; Kai-Nan Wu; Liang Ran; Ling-Quan Kong
Journal:  BMC Gastroenterol       Date:  2021-05-10       Impact factor: 3.067

10.  Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units.

Authors:  Xiaona Hu; Yiqin Huang; Zhijun Bao; Yiqian Wang; Dongmei Shi; Fang Liu; Zhanjuan Gao; Xiaofeng Yu
Journal:  BMC Gastroenterol       Date:  2012-09-14       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.